Faeth Therapeutics Inc(FTH) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 23 at 4:20 PM ET (Korea 10/24 05:20)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -141.65 | Insider Own | 28.82% | Shs Outstand | 25.8M | Perf Week | -9.15% |
| Market Cap | 0.44B | Forward P/E | - | EPS next Y | 78.82% | Insider Trans | 0.32% | Shs Float | 18.4M | Perf Month | -41.2% |
| Enterprise Value | 0.26B | PEG | - | EPS next Q | -0.78 | Inst Own | 48.29% | Short Float | 11.24% | Perf Quarter | -41.59% |
| Income | -0.20B | P/S | - | EPS this Y | 9.66% | Inst Trans | 56.8% | Short Ratio | 5.86 | Perf Half Y | -46.27% |
| Sales | 0.00B | P/B | 2.55 | EPS next 5Y | 39.51% | ROA | -176.88% | Short Interest | 2.07M | Perf YTD | 60.07% |
| Book/sh | 6.7 | P/C | 2.37 | EPS past 3/5Y | 19.15% -4.83% | ROE | -188.88% | 52W High | -59.47% ($42.14) | Perf Year | 63.29% |
| Cash/sh | 7.22 | P/FCF | - | Sales past 3/5Y | - | ROIC | -108.79% | 52W Low | 129.26% ($7.45) | Perf 3Y | 35.56% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -564.79% | Gross Margin | - | Volatility(W/M) | 12.35% 10.1% | Perf 5Y | -87.89% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 2.48 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 19.69 | EPS Q/Q | 27.54% | Profit Margin | - | RSI (14) | 26.5 | Recom | 1.12 |
| Dividend Gr. 3/5Y | - | Current Ratio | 19.69 | Sales Q/Q | - | SMA20 | -28.07% ($23.75) | Beta | -0.19 | Target Price | $56.14 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/4 | SMA50 | -43.47% ($30.21) | Rel Volume | 1 | Prev Close | $20.1 |
| Employees | 29 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -7.74% - | SMA200 | -31.59% ($24.97) | Avg Volume(3M) | 0.35M | Price | $17.08 |
| IPO | 2021/2/4 | Option/Short | No/Yes | Trades | 3482 | Volume | 353,714 | Change | -15.02% |
🧬 **FA**ce Therapeutics is a biotech company that targets metabolic pathways. By combining drugs that exploit cancer cells' metabolic dependencies with dietary modulation, the company is developing a clinical pipeline aimed at solid tumors such as endometrial cancer. It is a clinical-stage drug developer that positions its precision metabolic targeting strategy as its core differentiator.
Over the past 1 year, roughly in the middle
59% below its 1-year high.
Traded about as much as usual. That is 100% of its average volume.
FTH has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +9.7% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -87.9%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 48.3%.
Tap to view numbers
It ranks #227 of 595 in the industry
Based on market cap of $441M.
AGMB#225 AgomAb Therapeutics NV ADR $446M PER - 
MPLT#226 MapLight Therapeutics Inc $443M PER - FTH#227 Faeth Therapeutics Inc $441M PER - 
RGNX#228 Regenxbio Inc $441M PER - 
ALLO#229 Allogene Therapeutics Inc $432M PER - 
FAQ
What kind of company is FTH?
FTH belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of FTH?
The market cap of FTH is approximately $441M, ranking 3,251 within its sector.
What is the 52-week high and low for FTH?
FTH has recorded a 52-week high of $42.14 and a low of $7.45.
